PPARGC1α expression has been reported to be altered in neurodegenerative disorders, leading to mitochondrial defects and increased ROS levels; increasing its levels results in reductions in Alzheimer’s disease pathology and improvements in behavior (47). This evidence concerns the gene PPARGC1A and early-onset autosomal dominant Alzheimer disease.